Postpartum acquired factor VIII inhibitors.
The development of factor VIII autoantibodies is a rare but severe complication of pregnancy. Although the natural history of postpartum acquired hemophilia A is usually benign, with a high percentage of spontaneous remissions and a low mortality, its quick recognition is important to control bleeding episodes. Based on an analysis of the literature, this review presents the current knowledge on the pathogenesis, diagnosis, epidemiology, natural history, clinical manifestations, and therapeutic management of postpartum acquired hemophilia A.
Franchini
Massimo
M
Servizio di Immunoematologia e Trasfusione, Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy. mfranchini@univr.it
D001323:Autoantibodies / Q000097:blood; D003029:Coagulants / Q000627:therapeutic use; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D006473:Postpartum Hemorrhage / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology*; D011247:Pregnancy
D001323:Autoantibodies; D003029:Coagulants; D005169:Factor VIII